Compare Quest Diagnostics Inc (DGX) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs D R Horton Inc — how do they compare? Quest Diagnostics Inc trades at $237.55 (market cap $26.21B), while D R Horton Inc trades at $146.26 (market cap $42.18B). The key difference: D R Horton Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | DHI | |
|---|---|---|
Market Cap | $26.21B | $42.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $184.04 |
52-Week Low | $173.49 | $132.53 |
Enterprise Value | $31.97B | $47.28B |
Dividend Yield | 1.45% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
D.R. Horton (DHI) trades at $146.44, down slightly by 0.15% today, with a bullish technical signal from moving averages. The company reported Q3 2026 EPS of $3.20, beating estimates, but lowered full-year sales guidance due to soft demand. Valuation metrics appear reasonable with a P/E of 14.37 and P/S of 1.31, while profitability margins have compressed over recent years.
The outlook is mixed: strong cash flow and execution support the stock, but elevated mortgage rates and weak homebuying trends pose headwinds. Analyst consensus is a Buy with a $153 price target, indicating modest upside potential, though risks from housing market volatility persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
